A Phase Stratified, Randomized, Double-blind,Multicenter, Non-inferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quardavalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus in Subjects Ages

Project Details

StatusFinished
Effective start/end date30/10/1331/10/18

Funding

  • Novartis Pharmaceuticals: $88,546.00

Keywords

  • Biotechnology & Drug Development, Infectious Diseases